Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.23.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS    
Revenues, net $ 213,841 $ 48,272
Operating expenses:    
Cost of implants and other costs 15,279 5,881
Research and development 1,459,458 1,605,907
Selling, general and administrative 3,409,649 3,740,783
Impairment of intellectual property 0 141,480
Depreciation and amortization 27,450 64,328
Total operating expenses 4,911,836 5,558,379
Loss from operations (4,697,995) (5,510,107)
Other income (expenses):    
Interest expense - related parties (935,806) (546,260)
Interest expense, net (150,969) (19,424)
Loss on settlement of debt (198,939) 0
Loss on contingency (322,000) 0
Grant income 1,789,496 835,924
Other miscellaneous income 139,381 29,229
Total other income (expenses), net 321,163 299,469
Net loss before provision for income taxes (4,376,832) (5,210,638)
Income taxes 0 0
Net loss (4,376,832) (5,210,638)
Non-controlling interest 7,419 2,384
Dividend attributable to down round feature of warrants 0 (70,127)
Net loss attributable to BioCorRx Inc. $ (4,369,413) $ (5,278,381)
Net loss per common share, basic and diluted $ (0.61) $ (0.81)
Weighted average number of common shares outstanding, basic and diluted 7,198,312 6,491,067